Axcella

63 articles with Axcella

• Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021

  5/24/2021

  Activity demonstrated across targeted biologies, including amino acid balance, ammonia handling, muscle function and neurocognition Presentation includes new subject-specific neurocognition and muscle function data

• Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125

  5/11/2021

  Axcella Announces Initiation of EMMPACT SM Phase 2b Clinical Trial of AXA1125 Initial clinical sites activated and patient screening underway Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)

• Axcella Reports First Quarter 2021 Financial Results and Provides Business Update

  5/6/2021

  AxcellaAxcellaAxcellaAxcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

• Axcella to Report First Quarter 2021 Financial Results on May 6, 2021

  4/27/2021

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021.

• Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

  4/22/2021

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):

• Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH

  4/13/2021

  Multi-targeted oral candidate with the potential to be a first-line treatment option for adult and pediatric patients with NASH Phase 2b clinical trial in adults expected to begin in Q2

• Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  3/17/2021

  First IND application cleared by FDA for AXA1665 Initiation of AXA1665 Phase 2 clinical trial in OHE expected in Q2 2021 Initiation of AXA1125 Phase 2b clinical trial in NASH expected in Q2 2021 Company to host conference call at 8:30 a.m. ET today

• Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

  3/10/2021

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and full year 2020 financial results and other business updates on March 17, 2021.

• Axcella Announces Alison D. Schecter, M.D., as President of R&D

  3/3/2021

  Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development

• Axcella to Present at Upcoming Investor Conferences - Feb 18, 2021

  2/18/2021

  Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will participate in the following upcoming investor conferences

• Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones

  1/11/2021

  AXA1125 Phase 2b trial initiation planned for Q2 Company decides not to expand enrollment in AXA4010-001 following cohort 1 readout Pipeline expansion opportunities to be announced in 2021

• Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

  1/5/2021

  Presentation and webcast to take place at 10 a.m. ET on January 14

• Axcella Announces Upcoming Investor Conference Presentation - Nov 20, 2020

  11/20/2020

  Fireside chat at Piper Sandler 32nd Annual Virtual Healthcare Conference to be webcast on November 24

• Axcella Presents Data for AXA1125 at The Liver Meeting® 2020

  11/13/2020

  Poster presentations highlight AXA1125’s multifactorial activity; potentially differentiating and enhanced effects in subjects with type 2 diabetes

• Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/12/2020

  Plan to advance AXA1125 directly into a Phase 2b biopsy clinical trial in NASH under IND following successful Type B pre-IND meeting with FDA Plan to advance AXA1665 directly into a Phase 2 clinical trial in OHE under IND following positive top-line data from AXA1665-002 Published peer-reviewed manuscripts highlighting therapeutic benefit of EMMs and results from AXA1665-001 clinical study

• Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020

  10/29/2020

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter financial results and other business updates on November 12, 2020. The company will host a conference call at 8:30 a.m.

• Axcella Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020

  10/2/2020

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting ® 2020, the Annual Meeting of the American Association for the Study of Liver Dise

• New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)

  9/30/2020

  iScience review paper details use of amino acids in medicine Axcella focused on designing novel EMM compositions with the potential to tackle complex diseases; plans to advance lead candidates into later-stage clinical trials CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) com

• Axcella Announces Upcoming Investor Conference Presentation

  9/29/2020

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in a fireside chat at the H.C. Wainwright 4th Annual NASH In

• 

  BioSpace Movers & Shakers, Sept. 25

  9/25/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.